NYSE:NVST - Envista Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.60
  • Forecasted Upside: -4.48 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$43.55
▲ +0.78 (1.82%)

This chart shows the closing price for NVST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Envista Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVST

Analyst Price Target is $41.60
▼ -4.48% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Envista in the last 3 months. The average price target is $41.60, with a high forecast of $55.00 and a low forecast of $30.00. The average price target represents a -4.48% upside from the last price of $43.55.

This chart shows the closing price for NVST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Envista.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2021Morgan StanleyBoost Price TargetEqual Weight$42.00 ➝ $46.00Medium
5/6/2021Credit Suisse GroupBoost Price TargetOutperform$49.00 ➝ $55.00High
5/6/2021Piper SandlerBoost Price TargetNeutral$41.00 ➝ $45.00High
3/25/2021Credit Suisse GroupBoost Price TargetOutperform$44.00 ➝ $46.00Low
2/12/2021Morgan StanleyBoost Price TargetEqual Weight$36.00 ➝ $42.00Low
2/11/2021Credit Suisse GroupBoost Price TargetOutperform$41.00 ➝ $44.00Low
2/11/2021Piper SandlerBoost Price TargetNeutral$28.00 ➝ $41.00Low
1/8/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$31.00 ➝ $41.00Low
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$28.00 ➝ $36.00Low
11/25/2020Bank of AmericaBoost Price TargetNeutral$30.00 ➝ $32.00Low
11/2/2020Morgan StanleyBoost Price TargetEqual Weight$24.00 ➝ $28.00Medium
10/30/2020William BlairReiterated RatingOutperformLow
10/30/2020Piper SandlerBoost Price Target$22.00 ➝ $28.00High
10/30/2020JPMorgan Chase & Co.Boost Price TargetOverweight$28.00 ➝ $30.00High
10/30/2020Credit Suisse GroupBoost Price TargetNeutral$25.00 ➝ $31.00Low
10/30/2020JPMorgan Chase & Co.Reiterated RatingOverweight$28.00 ➝ $30.00High
9/15/2020Bank of AmericaBoost Price TargetNeutral$23.00 ➝ $27.00Low
8/3/2020Morgan StanleyBoost Price TargetEqual Weight$18.00 ➝ $24.00Low
7/31/2020Piper SandlerBoost Price TargetNeutral$20.00 ➝ $22.00Medium
7/20/2020Bank of AmericaBoost Price TargetNeutral$21.50 ➝ $23.00Low
6/16/2020Piper SandlerInitiated CoverageNeutral$20.00Medium
6/1/2020JPMorgan Chase & Co.Boost Price TargetOverweight$22.00 ➝ $24.00Low
5/14/2020Morgan StanleyLower Price TargetEqual Weight$20.00 ➝ $18.00Low
5/13/2020Robert W. BairdLower Price TargetOutperform$25.00 ➝ $23.00Low
5/13/2020Bank of AmericaReiterated RatingNeutral$19.50 ➝ $18.00High
5/13/2020Credit Suisse GroupLower Price TargetNeutral$23.00 ➝ $21.00High
3/17/2020JPMorgan Chase & Co.Lower Price TargetOverweight$32.00 ➝ $27.00High
12/17/2019Evercore ISIInitiated CoverageOutperformMedium
10/14/2019William BlairInitiated CoverageOutperformLow
10/14/2019Credit Suisse GroupInitiated CoverageNeutral$30.00Medium
10/14/2019JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Overweight$32.00 ➝ $32.00Medium
10/14/2019Stifel NicolausInitiated CoverageBuy$34.00Medium
10/14/2019Jefferies Financial GroupInitiated CoverageBuy$34.00Medium
10/14/2019The Goldman Sachs GroupInitiated CoverageBuy$33.00Medium
10/14/2019Robert W. BairdInitiated CoverageOutperform$33.00Medium
10/14/2019Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$29.00Medium
10/14/2019Evercore ISIInitiated CoverageOutperform$35.00Medium
10/14/2019Bank of AmericaInitiated CoverageNeutralMedium
(Data available from 6/22/2016 forward)
Envista logo
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
Read More

Today's Range

Now: $43.55
Low: $42.77
High: $43.76

50 Day Range

MA: $43.57
Low: $41.38
High: $45.48

52 Week Range

Now: $43.55
Low: $19.41
High: $46.52

Volume

966,939 shs

Average Volume

2,009,908 shs

Market Capitalization

$7.00 billion

P/E Ratio

64.04

Dividend Yield

N/A

Beta

1.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Envista?

The following Wall Street sell-side analysts have issued reports on Envista in the last year: Bank of America Co., Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, TheStreet, William Blair, and Zacks Investment Research.
View the latest analyst ratings for NVST.

What is the current price target for Envista?

5 Wall Street analysts have set twelve-month price targets for Envista in the last year. Their average twelve-month price target is $41.60, suggesting a possible downside of 4.5%. Credit Suisse Group AG has the highest price target set, predicting NVST will reach $55.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $30.00 for Envista in the next year.
View the latest price targets for NVST.

What is the current consensus analyst rating for Envista?

Envista currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVST will outperform the market and that investors should add to their positions of Envista.
View the latest ratings for NVST.

What other companies compete with Envista?

How do I contact Envista's investor relations team?

Envista's physical mailing address is 200 S. KRAEMER BLVD. BUILDING E, BREA CA, 92821. The company's listed phone number is 714 817 7000 and its investor relations email address is [email protected] The official website for Envista is www.envistaco.com.